RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
RBC Capital analyst Brian Abrahams maintains $Xenon Pharmaceuticals(XENE.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 49.
Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 25% Above Its Share Price
Key Insights Xenon Pharmaceuticals' estimated fair value is US$46.69 based on 2 Stage Free Cash Flow to Equity Xenon Pharmaceuticals is estimated to be 20% undervalued based on current share price o
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman
Express News | Xenon Pharmaceuticals Presents Phase 2 X-NOVA Clinical Trial Data Of Azetukalner in Major Depressive Disorder At ASCP 2024 Annual Meeting
Express News | Xenon Pharmaceuticals Presents Data From Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
Hedge Funds Are Racking Up Shares of This Healthcare Stock
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Express News | Xenon Pharmaceuticals Inc : JP Morgan Raises Target Price to $63 From $60
Xenon Pharmaceuticals Insiders Sell US$4.5m Of Stock, Possibly Signalling Caution
Over the past year, many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insiders sold a significant stake in the company which may have piqued investors' interest.
Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham
Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham
Xenon Pharmaceuticals Is Maintained at Buy by Citigroup
Xenon Pharmaceuticals Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Xenon Pharmaceuticals: A Strong Buy on Clinical Progress and Robust Financials
Xenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ...
Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush
Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush
Xenon Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 17.67% Wedbush $51 → $50 Maintains Outperform 04/12/2024 45.92% Needham → $62 Reiterates Buy →
Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating
Xenon Pharmaceuticals (XENE) has an average buy rating and a price target range of $45 to $63, according to analysts polled by Capital IQ.
Express News | Xenon Pharmaceuticals Inc : Citigroup Cuts Target Price to $60 From $62
Xenon Pharmaceuticals | 10-Q: Quarterly report
Xenon Pharma: Phase 3 Epilepsy Program Continues to Progress With Anticipated Completion of Patient Enrollment in X-TOLE2 in Late 2024 to Early 2025 >XENE
Xenon Pharma: Phase 3 Epilepsy Program Continues to Progress With Anticipated Completion of Patient Enrollment in X-TOLE2 in Late 2024 to Early 2025 >XENE
No Data